Castle Creek Biosciences, Inc. (CCBS)

Castle Creek Biosciences was planning to go public, but the IPO has been withdrawn.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Capn/a
Revenue (ttm)n/a
Net Income (ttm)-32.75M
Shares Outn/a
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Ex-Dividend Daten/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Price Targetn/a
Earnings Daten/a

About CCBS

Castle Creek Biosciences is a clinical-stage cell and gene therapy company focused on developing and commercializing disease-modifying therapies for patients suffering from rare diseases for which there is a lack of available treatment options. Our proprietary platform serves as the foundation for developing personalized, targeted and redosable cell-based gene therapy product candidates. At present, our novel in-house manufacturing process entails collecting minimally invasive skin biopsies from patients, and transducing fibroblast cells with a...

IndustryPharmaceutical Preparations
CEOMatthew Gantz
Stock ExchangeNASDAQ
Ticker SymbolCCBS
Full Company Profile

Financial Performance

Financial Statements


Rare disease biotech Castle Creek Biosciences files for a $100 million IPO

Castle Creek Biosciences, a Phase 3 biotech developing cell-based gene therapies for rare diseases, filed on Friday with the SEC to raise up to $100 million.

5 months ago - NASDAQ

Castle Creek Biosciences IPO Registration Document (S-1)

Castle Creek Biosciences, Inc. has filed to go public with an IPO on the NASDAQ.

5 months ago - SEC